key: cord-0812667-t4c90ue0 authors: Patel, Rahul A.; Torabi, Sina J.; Kasle, David A.; Manes, R. Peter title: Five-item odorant test as an indicator of COVID-19 infection in a general population date: 2022-01-29 journal: Am J Otolaryngol DOI: 10.1016/j.amjoto.2022.103376 sha: e330f92a7da450e4c3aef4bdda08f02c97d7d89f doc_id: 812667 cord_uid: t4c90ue0 PURPOSE: To analyze the utility of a 5-item odorant test (U-Smell-It™) in determining COVID-19 status in COVID-19 polymerase chain reaction (PCR)-positive and -negative participants. METHODS: Symptoms, COVID-19 status, and 5-item odorant test results were collected from general population COVID-19 testing in Louisiana (n = 1042), and routine COVID-19 screening of healthcare workers in a nursing home in Florida (n = 278) (ClinicalTrials.gov Identifier: NCT04431908). RESULTS: In the general population COVID-19 testing site, a cutoff point of ≤2 (0, 1, or 2 correct answers out of 5) achieved sensitivity of 40.0% (95% CI: 26.4%–54.8%) and specificity of 89.2% (95% CI: 87.1%–91.1%) in detecting COVID-19 infection. Within this population, analysis of individuals with no self-reported loss of smell/taste and runny/stuffy nose resulted in sensitivity of 38.1% (95% CI: 18.1%–61.6%) and specificity of 92.3% (95% CI: 89.1%–93.4%), while analysis of individuals with self-reported loss of smell/taste and/or runny/stuffy nose resulted in sensitivity of 41.4% (95% CI: 23.5%–61.1%) and specificity of 82.4% (95% CI: 77.7%–86.5%). CONCLUSIONS: The quick turnaround time, low cost, reduced resource requirement, and ease of administering odorant tests provide many advantages as an indicator sign to help flag a molecular diagnostic COVID-19 test with relatively high specificity. Our results suggest that this odorant testing for olfactory dysfunction may be a viable option in pre-screening COVID-19 infection. This tool has the potential to allow for continued monitoring and surveillance, while helping mitigate surges of COVID-19 variants. Further investigation is warranted to observe the extent to which odorant testing might be applied in a serial testing scenario. Temperature screening and symptom surveys, paired with polymerase chain reaction (PCR)-and antibody-based molecular tests, provide a means for (pre)-screening and diagnosing those at risk of having COVID-19, so as to mitigate infectious spread. However, in many middle-to lowerincome countries, molecular testing is expensive and can require specialized intrastructure; as such, there remains a need for convenient, inexpensive, and easy point-of-care (POC) and home self-administered tests with serial testing capacity 1, 2 This would allow for widespread, continued monitoring, while aiding in preparedness for expected future surges of COVID-19 and its variants. 2 Studies have indicated that odorant testing may be useful to identify patients in need of early treatment or quarantine. 3, 4 Though many varieties of commerciallyavailable odorant tests exist, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] these can be relatively costly (e.g. University of Pennsylvania Smell Identification Test [UPSIT] test costs circa $28-40) and are not easily amenable to large scale and repeated population COVID-19 surveillance. This study evaluates a new design of an olfactory test card (U-Smell-It™) with 5 odorants on a single card that could be deployed broadly. These ‗scratch and sniff'™ type devices are deemed safe by the FDA as they are non-invasive and non-toxic. The device card proposed here uses the same fragrance and microencapsulation process as used in the NIH Toolbox® tests for loss of smell. Further, the fragrances used in the U-Smell-It™ test kit are compliant with the International Fragrance Association, do not contain oils derived from nuts, wheat, or glutens, and do not use any phthalates or their derivatives. The device takes less than 60 seconds and the forced choice test has four-to-five odor options and a -no scent‖ option. We hypothesized that J o u r n a l P r e -p r o o f Journal Pre-proof RUNNING HEADER: COVID-19 Five-Item Odorant Test 4 this test can be an objective sign that may help identify infected individuals as part of an enhanced sign/symptom monitoring plan. This study was approved by the Yale Human Investigation Committee (IRB# 2000028259; ClinicalTrials.gov Identifier: NCT04431908), and focused on two cohorts: -drive-thru‖ outpatients seeking COVID-19 tests at a site affiliated with the State of Louisiana Office of Public Health in Central Louisiana (symptomatic group) and asymptomatic healthcare workers (HCWs) in a Florida nursing home undergoing routine PCR screening (asymptomatic group). Testing was performed in September and October of 2020. Patients and HCWs receiving COVID-19 testing were approached by a research team member to gauge interest, obtain consent, and ask screening questions. The test subjects used pencils to scratch back and forth the first window, sniff the window, then fill in the multiple choice circle (-no scent‖, and scent A, B, C or D). This procedure will be repeated for 5 windows. The subject was also asked the following questions: Test 5 Individuals were considered positive on the odorant test for COVID-19 if they got less than or equal to a certain amount of smells correct. Individuals in the general population COVID-19 testing site were split into two groups: symptomatic and asymptomatic. Due to the low prevalence of COVID-19 in the routine HCW testing population, this group was not split. Asymptomatic and symptomatic individuals were herein narrowly defined based on responses to the self-reported symptom questions which included (A) new loss of smell/taste and (B) runny/stuffy nose. Individuals that answered -yes‖ to at least one of these two questions were considered symptomatic and those that did not report either of these symptoms were considered asymptomatic. SPSS v27.0 (IBM Corp. Armonk, NY) was utilized for descriptive statistics, univariate (t-tests, chi-squared tests, Fischer's exact tests), and multivariable (logistical regression) tests of significance. The Johns Hopkins University web-based calculator for receiver operating characteristic (ROC) curves was used. 16 ROC curve graphs were created using Microsoft Excel (Redmond, CA). Significance was set at p<0.05. Youden's J statistic (Youden's index; sensitivity+specificity-1) was used in conjunction with ROC curves to help determine the optimal cut-off point for maximizing sensitivity and specificity. 17 Other cut-off points were also analyzed. Other descriptive statistics (e.g. sensitivity, specificity) were obtained using MedCalc. 18, 19 J o u r n a l P r e -p r o o f Journal Pre-proof Fifty SARS CoV-2 PCR positive individuals were confirmed in the general population COVID-19 testing site of 1042 (4.8% prevalence; Table 1 ). At time of testing, 12 (24.0%) of these PCR+ individuals reported new loss of either taste or smell, and 25 (50.0%) reported stuffy/runny nose ( p=0.001; Table 1 ). There was a significant difference in the mean olfactory score of PCR+ and PCR-individuals (2.90 vs. 4.02 out of 5; p<0.001; Table 1 ; Figure 1 ). The ability for the odorant test to indicate COVID-19 infection was assessed using a ROC curve analysis. The sensitivity and specificity for different number of correct answers (0 to 4 out of 5) were determined, as well at the Younden's index at each cutoff ( Table 2) . For the total general population COVID-19 testing site, Youden's index yielded a maximal value of 0.305 (Sensitivity=0.56; Specificity=0.75) at a cutoff point of ≤3 correct answers (i.e., 0, 1, 2, or 3 out of 5 questions correct indicating positive odorant test for olfactory dysfunction, and therefore potentially COVID-19) ( Table 2 ). Symptomatic individuals were defined as those who reported new loss of either taste or smell and/or stuffy/runny nose. In the symptomatic population (n=313), Youden's index yielded a maximal value of 0.336 at a cutoff point of ≤3 correct answers (Table 2 ). In the asymptomatic for loss of smell/taste or runny/stuffy nose population (n=729), Youden's index yielded a maximal value of 0.267 at a cutoff point of ≤2 correct answers ( Table 2) . With our goals of balancing sensitivity and specificity, and maximizing the accuracy and odds ratio, while minimizing falses positives, a cutoff point of ≤2 correct answers was used for all further analysis of the general population COVID-19 testing site due to its overall better performance in all of the aforementioned metrics. A cutoff point of ≤2 correct answers achieved a sensitivity of 40.00% (95% CI: 26.41%-54.82%) and a specificity of 89.21% (95% CI: 87.12%-91.08%) in screening for COVID-19 (Table 3) . Overall accuracy was 86.85% (95% CI: 84.65%-88.85%) with an OR of 5.51 (95% CI: 3.03-10.05; p<0.001) ( Table 3 ). The PPV was 15.75% (95% CI: 11.30%-21.53%), and NPV was 96.72% (95% CI: 95.92%-97.37%) ( Table 3) . LR+ was 3.71 (95% CI: 2.53-5.44) and LR-was 0.67 (95% CI: 0.54-0.84) ( Table 3) . Area under the ROC curve was 0.684 ( Figure 2 ; Table 2 ). Among asymptomatic for loss of smell/taste or runny/stuffy nose individuals in this group Table 3 ). Area under the ROC curve was 0.612 ( Figure 2 ; Table 2 ). Although all individials in this group had no nasal obstruction/runny nose, or selfperception of loss of smell, when using an olfactory test with an olfactory dysfunction cutoff of ≤2, almost 40% actually had olfactory loss that was associated with being positive for SARS Table 3) . Area under the ROC curve was 0.708 ( Figure 2 ; Table 2 ). To identify what factors contribute to a false positive test result, (COVID-19 PCR-, but positive on the odorant test) univariate and multivariate logistical regression models were created that predicted false positives (relative to true negatives There were only 2 (0.72%) PCR+ individuals in the routine HCW testing population (n=278) (Supplemental Table 1 ). One subject, who got 1/5 correct, reported no symptoms and the other, who got 5/5 correct, only reported stuffy/runny nose (Supplemental Table 1 ). Neither reported a loss of smell of in the questionnaire. Data on particular cutoffs is provided in Supplemental infection. 21 The sensitivity of an olfactory test is considerably lower than that of molecular tests, however lower sensitivity can be compensated for by serial testing. 21, 22 The actual optimal cutoff will depend on the context of screening. If a secondary reflux test is available, higher sensitivity thresholds can be used, at the cost of decreased specificity. It is worth noting that while about 40% of individuals that had no self-reported loss of smell or any kind of nasal obstruction (stuffy or runny nose) actually had, when tested with an olfactory test, an olfactory dysfunction (sensitivity ~38%; cutoff ≤2). Key benefits of our study are: i) inclusion of COVID-19 PCRindividuals, which is critical for balancing sensitivity and specificity, and ii) a very large total sample size (over one thousand total individuals). In the general population COVID-19 testing site, there was a significantly greater proportion of individuals in the PCR+ cohort that reported new loss of either taste or smell (12 [ 4 Though stuffy/runny nose has only been anecdotally reported as a symptom in COVID-19 positive patients, [23] [24] [25] our results indicate that stuffy/runny nose may be a weak indicator for COVID-19 infection, and warrants further evaluation. At a cutoff point of ≤2 correct, we were unable to reach a >80% sensitivity in the general population COVID-19 testing site, which indicates that this smell test has a moderate ability to discriminate between PCR+ and PCR-patients. However, when the individuals became positive is not known and at the time the population was examined (September-October 2020), the recent surge had passed and cases were droppingthus it is conceivable that a fraction of people were tested well post their exposure. As raised elegantly by others, 26 a PCR tests identifies for the presence of genetic material, but does not identify if the person is still infective. In general, infectivity lasts about 10 days while an individual can be PCR positive for ~30 days. Thus, it is likely that some of the individuals were PCR positive but no longer infectious. As the duration of loss of smell is known to be ~7-14 day 21 it would be expected that some people will recover from anosmia/hyposmia but still be PCR positive. Thus it should be taken that PCR is a reference test and not a gold standard for what matters, which is SARS CoV-2 infectiousness. In an attempt to find specific cohorts where the test might be more useful, we split the general population COVID-19 testing site into symptomatic and asymptomatic groups (based on loss of smell/taste or runny/stuffy nose). Though results were similar when using a cutoff of ≤2, the sensitivity was slightly higher with the symptomatic group (41.4% vs 38.1% aymptomatic) but specificity was 10% higher with asymptomatic for loss of smell/taste or runny/stuffy nose group (92.3% vs 82.4% sympotmatic). This likely reflects that there is some non-specific olfactory dysfunction with a blocked or stuffy nose. Thus, when high specificity is paramount, individuals with a stuffy nose may be excluded at some cost of sensitivity. Though higher cutoffs such as ≤4 correct were able to achieve sensitivity >80% in the symptomatic group (85.2%), specificity was greatly lower (39.2%), which we found to be associated with increasing age (>67). This raises the possibility that this test might perform better among a cohort of younger individuals, who comprise a greater proportion of the workforce and resource-deficient countries, increasing support for use in these settings. Lower cut-off points, such as ≤2 questions correct, resulted in greater specificity (89.2%), accuracy (86.9%), and OR (5.5), though sensitivity was much lower (40.0%). Though the performance of a 10-odor test was only slightly better than a 5-odor test, as implicated by Lessa et al., 21 there is a possibility that using a lower cut-off point in conjunction with serial testing could help alleviate the reduced sensitivity of a lower cut-off. It has been shown that a low-sensitivity and high-specificity test when used in a high frequency manner was suitable for mitigating outbreaks, especially if the test cost was minimal. 22 HCWs are an interesting and useful population as all reported no COVID-19 related symptoms as part of their daily surveys. Interestingly, one of two COVID-19 positive subjects had severe hyposmia (score of 1/5), although they did not recognize their hyposmia. These data do fit with other reports that asympotomatic COVID-19 positive people can have unrecognized mild-tosevere hyposmia. 27 The weakness of this arm of the study was the low prevalence, exemplifying the challenge in testing asymptomatic people-it will require a large sample size (several thousands) to be statistically robust. One current rapid mainstream method of screening patients for COVID-19 has been with body temperature measuments of fever (>38 o C) although it has shown very low performance in infection. 28 Due to low numerosity, the study was unable to test this endpoint with a reasonable amount of certainty. 28 Though anosmia and olfactory dysfunction have been reported as symptoms of COVID-19 infection, 29, 3 our results seem to suggest that an odor identification test has only moderate sensitivity as a single timepoint screening mechanism, although it could be an addition to the Swiss Cheese Model to provide a multilayer mechanism for pandemic defense. 30 Limitations of this study include the self-reporting nature of symptoms, which put the study at risk for recall bias with regards to differentiation of asymptomatic and symptomatic individuals. Only adults were tested and how the results translate to children is unclear, although other reports indicate that ~86% of COVID-19+ children may have hyposmia. 31 dysfunction, but then turned positive the next day, the prevalence would be higher than the sensitivity based on one day of testing. Furthermore, olfactory testing has its own inherent limitations that may have hindered its effective use. As the pandemic matures and resources devoted to detecting COVID-19 de-intensify, there remains a need for an effective tool to detect infection, especially in resource-deficient settings or those with a low degree of vaccine immunization. Our results suggest that odorant testing to detect olfactory dysfunction may be a viable option in detecting COVID-19 infection and could potentially be an addition to the Swiss Cheese Model to provide a multilayer mechanism for pandemic defense. Though further investigation in longitudinal studies is warranted to observe the extent to which odorant testing could be used to supplement traditional clinical judgement and the potential benefits of serial testing, our preliminary analysis suggests moderate discriminatory ability. COVID-19) Update: FDA takes steps to streamline path for COVID-19 screening tools, provides information to help groups establishing testing programs. United States Food and Drug Administration Assa'ad A. Clinical testing for COVID-19 Smell dysfunction: a biomarker for COVID-19 Smell and taste symptom-based predictive model for COVID-19 diagnosis Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT). The Laryngoscope University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. The Laryngoscope -Sniffin‖ sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold Influences of Age and Sex on a Microencapsulated Odor Memory Test Utility of a three-item smell identification test in detecting olfactory dysfunction. The Laryngoscope Olfactory assessment using the NIH Toolbox The Taste and Smell Protocol in the 2011-2014 US National Health and Nutrition Examination Survey (NHANES): Test-Retest Reliability and Validity Testing Odor Mixtures in Identification Testing Using Sniffin' Sticks: The SSomix Test The Pocket Smell Test: successfully discriminating probable Alzheimer's dementia from vascular dementia and major depression Test-Retest Reliability and Validity of the Sniffin' TOM Odor Memory Test A study of the relationship between the T&T olfactometer and the University of Pennsylvania Smell Identification Test in a Japanese population ROC Analysis: Web-based Calculator for ROC Curves Partial Youden index and its inferences Diagnostic test evaluation calculator Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis The Usefulness of a Quantitative Olfactory Test for the Detection of COVID-19. Infectious Diseases (except HIV/AIDS) COVID-19 screening strategies that permit the safe reopening of college campuses Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg Taste and Smell Impairment in COVID-19: An AAO-HNS Anosmia Reporting Tool-Based Comparative Study. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg COVID-19 Five-Item Odorant Test Rethinking Covid-19 Test Sensitivity -A Strategy for Containment Quantitative assessment of olfactory dysfunction accurately detects asymptomatic COVID-19 carriers SCENTinel 1.0: development of a rapid test to screen for smell loss World Health Organization (WHO) Safe hospital preparedness in the era of COVID-19: The Swiss cheese model Smell Status in Children Infected with SARS-CoV-2. The Laryngoscope COVID-19 Five-Item Odorant Test The authors would like to thank U-Smell-It™ LLC for kindly providing the olfactory tests.Olfactory tests were provided at no cost by the manufacturer (U-Smell-It LLC). The manufacturer was sponsored through prevision of the test material and mailed it to the test location. No members of the company were involved in the actual study (data collection, analysis, etc). Additionally, we would like to thank Dr. Basemah Gheith, Dr. David Holcombe, and Dr. Joseph Gannett for their assistance in acquiring data.